Batard Thierry, Taillé Camille, Guilleminault Laurent, Bozek Andrzej, Floch Véronique Bordas-Le, Pfaar Oliver, Canonica Walter G, Akdis Cezmi, Shamji Mohamed H, Mascarell Laurent
Innovation & Science Department, Stallergenes Greer, Antony, France.
Service de Pneumologie et Centre de référence pour les maladies respiratoires rares, Hôpital Bichat, AP-HP Nord-Université Paris Cité, Paris, France.
Clin Exp Allergy. 2025 Feb;55(2):111-141. doi: 10.1111/cea.14575. Epub 2024 Oct 4.
Allergic asthma is the predominant phenotype among asthmatics. Although conventional pharmacotherapy is a central component in the management of asthma, it does not enable control of asthma symptoms in all patients. In recent decades, some uncontrolled asthmatic patients, especially those with allergic asthma, have benefited from biological therapies. However, biologics do not address all the unmet needs left by conventional pharmacotherapy. Furthermore, it is noteworthy that neither conventional pharmacotherapy nor biological therapies have disease-modifying properties. In this context, allergen immunotherapy (AIT) represents an indispensable component of the therapeutic arsenal against allergic asthma, due to its disease-modifying immunological effects. In this review article, funded by an AIT manufacturer, we find clinical trials support AIT as the only treatment option able both to improve allergic asthma symptoms and to prevent the onset and worsening of the condition. For patients with severe asthma or other safety concerns, the combination of AIT and biologics offers very promising new treatment modalities for the management of allergic asthma. Trial Registration: clinicaltrials.gov identifier: NCT06027073.
过敏性哮喘是哮喘患者中最主要的表型。尽管传统药物治疗是哮喘管理的核心组成部分，但它并不能使所有患者的哮喘症状得到控制。近几十年来，一些未得到控制的哮喘患者，尤其是过敏性哮喘患者，从生物疗法中获益。然而，生物制剂并不能满足传统药物治疗留下的所有未满足的需求。此外，值得注意的是，传统药物治疗和生物疗法都没有改变疾病的特性。在这种情况下，变应原免疫疗法（AIT）由于其改变疾病的免疫效应，成为治疗过敏性哮喘的治疗手段中不可或缺的组成部分。在这篇由一家AIT制造商资助的综述文章中，我们发现临床试验支持AIT是唯一既能改善过敏性哮喘症状又能预防病情发作和恶化的治疗选择。对于重度哮喘患者或有其他安全问题的患者，AIT与生物制剂的联合为过敏性哮喘的管理提供了非常有前景的新治疗模式。试验注册：clinicaltrials.gov标识符：NCT06027073。
